TAK-659 clinical trials
Also written TAK-659.
A product of Mivavotinib; its studies count on that page too.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses TAK-659 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TAK-659
- 10
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Calithera Biosciences, Inc (9) · H Scott Boswell (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Mivavotinib
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses TAK-659 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor IxazomibTerminatedPhase 1/2H Scott BoswellNCT04079738Written as TAK-659How we know
- A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedPhase 1Calithera Biosciences, IncNCT03357627Written as TAK-659How we know
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesCompletedPhase 1Calithera Biosciences, IncNCT02000934Written as TAK-659How we know
- Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedPhase 1/2Calithera Biosciences, IncNCT02323113Written as TAK-659How we know
- A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)TerminatedPhase 1Calithera Biosciences, IncNCT03238651Written as TAK-659How we know
- TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedPhase 2Calithera Biosciences, IncNCT03123393Written as TAK-659How we know
- A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedPhase 1Calithera Biosciences, IncNCT02834247Written as TAK-659How we know
- A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma MalignanciesWithdrawnPhase 1Calithera Biosciences, IncNCT03338881Written as [14C]-TAK-659How we know
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnPhase 1Calithera Biosciences, IncNCT03772288Written as TAK-659How we know
- A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid TumorWithdrawnPhase 1Calithera Biosciences, IncNCT03359733Written as TAK-659How we know
Given beside what is tested · 2 — TAK-659 is usual care or a partner of the new treatment
- A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02954406Written as TAK-659How we know
- MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal AdenocarcinomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02551055Written as TAK-659How we know